Mubadala Investment Company 收购专业制药公司 Kelix Bio，以加强阿联酋的生命科学生态系统。 Mubadala Investment Company acquires Kelix Bio, a specialty pharmaceutical firm, to bolster UAE's life sciences ecosystem.
阿布扎比的战略投资部门穆巴达拉投资公司将收购专注于新兴市场的专业制药公司Kelix Bio。 Mubadala Investment Company, Abu Dhabi's strategic investment arm, is set to acquire Kelix bio, a specialty pharmaceutical company focusing on emerging markets. 此次收购旨在加强阿联酋的生命科学生态系统，并使该国成为生命科学和制药领域的全球领导者。 The acquisition aims to strengthen the UAE's life sciences ecosystem and position the country as a global leader in life sciences and pharmaceuticals. Kelix Bio 成立于 2020 年 11 月，已收购了印度、埃及、马耳他和摩洛哥的生产设施，专门生产用于各个治疗领域的复杂仿制药。 Kelix bio, founded in November 2020, has acquired manufacturing facilities in India, Egypt, Malta, and Morocco, specializing in complex generics for various therapy areas.